c102763.htm - Generated by SEC Publisher for SEC Filing

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

MAY 26, 2010

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 


 

logo.gif

Company Announcement

25 May 2010

Novo Nordisk A/S – Share repurchase programme

On 27 April 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 27 April 2010 to 3 August 2010.

Since the announcement as of 17 May 2010, the following transactions have been made under the programme:

 

Number of

shares

Average

purchase price

Transaction value,

DKK

Accumulated, last

announcement

950,500

 

439,079,282

17 May 2010

52,500

469.9820

24,674,055

18 May 2010

72,500

476.8651

34,572,720

19 May 2010

77,000

467.0950

35,966,315

20 May 2010

165,000

457.4987

75,487,286

21 May 2010

143,000

442.6057

63,292,615

Accumulated under

the programme

1,460,500

 

673,072,272

 

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 2,000 B shares in the period from 17 May 2010 to 21 May 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

Company Announcement no 27 / 2010

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

With the transactions stated above, Novo Nordisk owns a total of 36,210,372 treasury shares, corresponding to 5.8% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

 

 

Media:

Investors:

 

Elin K Hansen

Klaus Bülow Davidsen

Tel: (+45) 4442 3450

Tel: (+45) 4442 3176

ekh@novonordisk.com

klda@novonordisk.com

 

 

Kasper Roseeuw Poulsen

 

Tel: (+45) 4442 4471

 

krop@novonordisk.com

 

In North America:

In North America:

Sean Clements

Hans Rommer

Tel: (+1) 609 514 8316

Tel: (+1) 609 919 7937

secl@novonordisk.com

hrmm@novonordisk.com

 

Company Announcement no 27 / 2010

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: MAY 26, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer